Cargando…
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as th...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223191/ https://www.ncbi.nlm.nih.gov/pubmed/34165650 http://dx.doi.org/10.1007/s10072-021-05409-6 |